Tiziana Life Sciences (NASDAQ:TLSA) focuses on innovative therapies and drug delivery technologies for immunotherapy. The company's nasal approach could potentially improve efficacy, safety, and tolerability compared to intravenous delivery. Tiziana's pipeline and technology are protected by patents, with several applications pending. While the company operates with a moderate debt level and currently shows a current ratio of 0.85, InvestingPro data indicates its overall financial health score remains fair, suggesting potential for future growth despite current challenges. While the company operates with a moderate debt level and currently shows a current ratio of 0.85, InvestingPro data indicates its overall financial health score remains fair, suggesting potential for future growth despite current challenges.
These universities are recognized for their contributions to medical research, particularly in neurology and multiple sclerosis. The inclusion of these sites is expected to enhance the reach and quality of the trial, leveraging their expertise and state-of-the-art facilities. The trial participants will undergo PET scans at Invicro in New Haven, Connecticut, to ensure scan consistency.
Non-active SPMS, a condition with currently no FDA-approved treatments, is marked by a lack of disease flare-ups but a gradual increase in disability. Tiziana's intranasal foralumab, the only fully human anti-CD3 monoclonal antibody, is designed to modulate the immune system without causing systemic immune suppression. It has been shown to stimulate T regulatory cells, which are crucial in controlling the inflammatory process.
Tiziana Life Sciences focuses on innovative therapies and drug delivery technologies for immunotherapy. The company's nasal approach could potentially improve efficacy, safety, and tolerability compared to intravenous delivery. Tiziana's pipeline and technology are protected by patents, with several applications pending. While the company operates with a moderate debt level and currently shows a current ratio of 0.85, InvestingPro data indicates its overall financial health score remains fair, suggesting potential for future growth despite current challenges.
Intranasal foralumab is currently under investigation in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial. An open-label Expanded Access Program has reported either improvement or stability in all 10 na-SPMS patients treated within 6 months. The FDA has recently approved the inclusion of an additional 20 patients in this program.
Tiziana Life Sciences focuses on innovative therapies and drug delivery technologies for immunotherapy. The company's nasal approach could potentially improve efficacy, safety, and tolerability compared to intravenous delivery. Tiziana's pipeline and technology are protected by patents, with several applications pending.
This news is based on a press release statement from Tiziana Life Sciences.
In other recent news, Tiziana Life Sciences Ltd has disclosed its interim financial results for the first half of 2024, along with updates on its lead development programs. The company has successfully secured a $4 million grant from the National Institutes of Health (NIH) for Alzheimer's research, focusing on the potential use of intranasal foralumab as a therapy. The firm's intranasal formulation of foralumab also received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
Ivor Elrifi has been appointed as the new CEO of Tiziana, who will lead the ongoing clinical trials for intranasal foralumab. The company has also secured $3.4 million in non-dilutive funding to advance its Phase 2 clinical trial of intranasal foralumab for na-SPMS.
In compliance with Nasdaq's minimum bid price requirement, Tiziana's securities will continue to be listed on the Nasdaq Stock Market. The FDA has approved the expansion of Tiziana's Expanded Access program for intranasal foralumab, now including 30 patients. Lastly, it was reported that 80% of the participants in an Expanded Access Program showed a qualitative reduction in microglial activity after six months of treatment with intranasal foralumab. These are the latest developments in Tiziana Life Sciences Ltd's ongoing operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.